ACM
TGTX icon

Altium Capital Management’s TG Therapeutics TGTX Stock Holding History

Altium Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,000
Closed -$2.86M – 66
2024
Q4 		$2.86M Buy
+95,000
New +$2.73M 0.81% 38

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Altium Capital Management's TGTX Position: Q1 2025 in Review

Altium Capital Management sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 95,000 shares — an estimated $2.86M sold.

Altium Capital Management first reported a position in TGTX in Q4 2024 and held it in 1 quarter. The position peaked at $2.86M in Q4 2024. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • Altium Capital Management reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 95,000 TG Therapeutics shares in Q1 2025, an estimated $2.86M.
  • Altium Capital Management first reported a position in TG Therapeutics in Q4 2024 and held it in 1 quarter.
  • Altium Capital Management's TG Therapeutics position peaked at $2.86M in Q4 2024.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.